ClinicalTrials.gg
CompletedNCT04085601Updated Oct 21, 2022Results posted

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

A Phase 3 interventional study of APL-2 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand — 2 open to participants now, 4 under way, 3 of them phase 3. Hemoglobinuria, Paroxysmal · Thailand.

Enrollment
7th of 10
53 · median 83
Started
2019
with 1 other
Phase 3
8 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Apellis Pharmaceuticals, Inc.

Among the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 4th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

2 of the 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal with a site in Thailand, or all of them as a file.
02

Study summary

Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years old (inclusive).
  • Have LDH ≥1.5 x at the screening visit.
  • Have PNH diagnosis, confirmed by high sensitivity flow cytometry (granulocyte or monocyte clone >10%).
  • Have less than the lower limit of normal (LLN) at the screening visit.
  • Have ferritin greater than/equal to the LLN, or total iron binding capacity (TIBC) less than/equal to ULN at the screening visit, based on central laboratory reference ranges. If a subject is receiving iron supplements at screening, the Investigator must ensure that the subject's dose has been stable for 4 weeks prior to screening, and it must be maintained throughout the study. Subjects not receiving iron at screening must not start iron supplementation during the course of the study.
  • (BMI) ≤ 35 kg/m2 at the screening visit.
  • Have a count of >50,000/mm3 at the screening visit.
  • Have an >500/mm3 at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any complement inhibitor (eg, eculizumab) within 3 months prior to screening.
  • Hereditary complement deficiency.
  • History of bone marrow transplantation.
  • Concomitant use of any of the following medications is prohibited if not on a stable regimen for the time period indicated below prior to screening:

    • Erythropoietin or for at least 8 weeks
    • Systemic for at least 4 weeks
    • Vitamin K antagonists (eg, warfarin) with a stable (INR) for at least 4 weeks
    • Iron supplements, vitamin B12, or folic acid for at least 4 weeks
    • Low-molecular-weight heparin for at least 4 weeks
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • No intervention
    Standard of Care (SOC) excluding complement inhibitors
  • Experimental
    1,080mg APL-2 administered subcutaneously twice weekly

    Drug: APL-2

Interventions

  • DrugAPL-2

    Complement (C3) Inhibitor

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization

    The Hb stabilization was defined as avoidance of a \>1 gram per deciliter (g/dL) decrease in Hb concentration from Baseline in the absence of transfusion through Week 26.

    Time frame: From Baseline (Day 1) up to Week 26

  2. Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26

    The LDH concentration was analyzed using an analysis of covariance (ANCOVA) model with a last observation carried forward (LOCF) and a baseline observation carried forward (BOCF) approach for handling missing data. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

    Time frame: Baseline (Day 1) and Week 26

Secondary outcomes

  1. Number of Subjects With an Hb Response in the Absence of Transfusions

    An Hb response was defined as a =\>1 g/dL increase in Hb from baseline at Week 26.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Absolute Reticulocyte Count (ARC) at Week 26

    Blood samples were collected via direct venipuncture at the specific time points to determine ARC. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

    Time frame: Baseline and Week 26

  3. Change From Baseline in Hb Concentration at Week 26

    Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

    Time frame: Baseline and Week 26

  4. Percentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline

    Transfusion refers to any transfusion of PRBC, leukocyte-depleted red blood cells (LDPRC), leukocyte poor packed red blood cell (LPRC), leukocyte poor blood (LPB) or whole blood.

    Time frame: At Week 26

  5. Percentage of Subjects With Transfusion Avoidance

    Transfusion avoidance was defined as the percentage of subjects who did not require a transfusion during the RCP. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

    Time frame: At Week 26

  6. Number of PRBC Units Transfused From Baseline Through Week 26

    The number of units of PRBC transfusions was estimated. In one transfusion subjects received one or more units.

    Time frame: Up to Week 26

  7. Change From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 26

    The FACIT-Fatigue Scale is a 13-item Likert scaled instrument that is self-administered by the subjects during clinic visits. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses are "Not at all" (0), "A little bit" (1), "Somewhat" (2), "Quite a bit" (3), and "Very much" (4). With 13 statements, the total score has a range of 0 to 52. The higher score corresponded to a higher quality of life. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

    Time frame: Baseline and Week 26

  8. Percentage of Subjects With Hb Normalization Levels at Week 26

    Normalization of Hb levels defined as \>= 1x LLN at Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

    Time frame: Baseline and Week 26

  9. Percentage of Subjects With LDH Normalization at Week 26

    The LDH normalization was defined as LDH \<= 1xupper limit of normal (ULN) of normal range at week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPPRC, LPRC, LPB or whole blood.

    Time frame: At Week 26

  10. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 26

    The EORTC QLQ-C30 questionnaire (version 3.0) consisted of 30 questions comprised of both multi-item scales and single-item measures to assess overall quality of life in subjects. Questions were designated by functional scales, symptom scales, and global subject QOL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). Each scale has a range of 0% - 100%. A high scale score represents a higher response level. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

    Time frame: Baseline and Week 26

  11. Change From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 26

    The LASA consisted of 3 items asking respondents to rate their perceived level of functioning. Specific domains include activity level, ability to carry out daily activities, and an item for overall QOL. Their level of functioning was reported on a 0-100 scale with 0 representing "As low as could be" and 100 representing "As high as could be".

    Time frame: Baseline and Week 26

  12. Percentage of Subjects With ARC Normalization

    Absolute reticulocyte count normalization is defined as ARC \< 1x ULN of the gender-specific normal range at week 26 in the absence of transfusion. Subjects who received a transfusion or withdraw from study or escaped from SoC to pegcetacoplan treatment group or lost to follow up without providing efficacy data at Week 26 were classified as non-responders. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

    Time frame: At Week 26

  13. Number of Subjects With Failure of Hb Stabilization

    Hb stabilization is defined as avoidance of a \>1 g/dL decrease in Hb levels from baseline through Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

    Time frame: Up to Week 26

  14. Time to First PRBC Transfusion

    Time to first-on-study PRBC transfusions during RCP were reported. Here NA indicates not estimable.

    Time frame: Up to Week 26

07

Results

Posted Oct 21, 2022

Participant flow

This study was conducted in subjects with paroxysmal nocturnal hemoglobinuria (PNH) at 22 investigational sites. The study consisted of a screening period (up to 4 weeks), followed by a randomized controlled period (RCP) (26 weeks). All subjects who completed RCP rolled over into a separate open-label, long-term extension study (APL2-307) or completed the safety follow-up (34 weeks).

Participant flow — Overall Study
MilestonePegcetacoplanStandard of Care
Started3518
Soc to pegcetacoplan (escape therapy)011
Completed3317
Not completed21
Withdrew: Lost to follow-up10
Withdrew: Death11

Outcome measures

PrimaryNumber of Subjects Who Achieved Hemoglobin (Hb) Stabilization

The Hb stabilization was defined as avoidance of a \>1 gram per deciliter (g/dL) decrease in Hb concentration from Baseline in the absence of transfusion through Week 26.

Time frame:
From Baseline (Day 1) up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization
ParticipantsPegcetacoplanStandard of Care
Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization300
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test is stratified by number of packed red blood cell (PRBC) within 12 months prior to screening (\<4, ≥ 4) reported in electronic data capture (EDC) data.) · Difference: 0.7311 · 95% CI 0.572 to 0.8902
PrimaryChange From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26

The LDH concentration was analyzed using an analysis of covariance (ANCOVA) model with a last observation carried forward (LOCF) and a baseline observation carried forward (BOCF) approach for handling missing data. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Least squares mean · Units/Liter (U/L)
Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26
Units/Liter (U/L)PegcetacoplanStandard of Care
Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26-1870.47 ± 100.971-400.09 ± 312.988
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = <0.0001 (p-value for Baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: -1470.38 · 95% CI -2113.44 to -827.32
SecondaryNumber of Subjects With an Hb Response in the Absence of Transfusions

An Hb response was defined as a =\>1 g/dL increase in Hb from baseline at Week 26.

Time frame:
Baseline and Week 26
Reported as:
Count of participants · Participants
Number of Subjects With an Hb Response in the Absence of Transfusions
ParticipantsPegcetacoplanStandard of Care
Number of Subjects With an Hb Response in the Absence of Transfusions251
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test is stratified by number of PRBC within 12 months prior to screening (\<4, ≥ 4) reported in EDC data.) · Difference: 0.5411 · 95% CI 0.339 to 0.7431
SecondaryChange From Baseline in Absolute Reticulocyte Count (ARC) at Week 26

Blood samples were collected via direct venipuncture at the specific time points to determine ARC. Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · 10^9 cells/L
Change From Baseline in Absolute Reticulocyte Count (ARC) at Week 26
10^9 cells/LPegcetacoplanStandard of Care
Change From Baseline in Absolute Reticulocyte Count (ARC) at Week 26-123.26 ± 9.164-19.44 ± 25.209
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = 0.0002 (P-value for Baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: -103.82 · 95% CI -158.9 to -48.74
SecondaryChange From Baseline in Hb Concentration at Week 26

Baseline was defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · g/dL
Change From Baseline in Hb Concentration at Week 26
g/dLPegcetacoplanStandard of Care
Change From Baseline in Hb Concentration at Week 262.94 ± 0.3830.27 ± 0.759
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = 0.0019 (P-value for baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: 2.67 · 95% CI 0.99 to 4.35
SecondaryPercentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline

Transfusion refers to any transfusion of PRBC, leukocyte-depleted red blood cells (LDPRC), leukocyte poor packed red blood cell (LPRC), leukocyte poor blood (LPB) or whole blood.

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline
percentage of subjectsPegcetacoplanStandard of Care
Percentage of Subjects Who Received Transfusion or Decrease of Hb >2 g/dL From Baseline11.4100
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test is stratified by number of PRBC within 12 months prior to screening (\<4, ≥4) reported in EDC data.) · Difference: -0.7505 · 95% CI -0.9041 to -0.5969
SecondaryPercentage of Subjects With Transfusion Avoidance

Transfusion avoidance was defined as the percentage of subjects who did not require a transfusion during the RCP. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects With Transfusion Avoidance
percentage of subjectsPegcetacoplanStandard of Care
Percentage of Subjects With Transfusion Avoidance91.45.6
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test is stratified by number of PRBC within 12 months prior to screening (\<4, ≥4) reported in EDC data.) · Difference: 0.7241 · 95% CI 0.5583 to 0.8899
SecondaryNumber of PRBC Units Transfused From Baseline Through Week 26

The number of units of PRBC transfusions was estimated. In one transfusion subjects received one or more units.

Time frame:
Up to Week 26
Reported as:
Median · PRBC transfusions
Number of PRBC Units Transfused From Baseline Through Week 26
PRBC transfusionsPegcetacoplanStandard of Care
Number of PRBC Units Transfused From Baseline Through Week 260.0 (0 to 19)3.0 (0 to 13)
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Wilcoxon Rank-Sum Test · p = <0.0001 (Wilcoxon rank-sum test p-value for the comparison between treatments is based on median using stratified non-parametric analysis. The 95% confidence interval (CI) is constructed using Hodges-Lehmann Estimation of Location Shift.) · Median difference (net): 3 · 95% CI 2 to 4
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 26

The FACIT-Fatigue Scale is a 13-item Likert scaled instrument that is self-administered by the subjects during clinic visits. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses are "Not at all" (0), "A little bit" (1), "Somewhat" (2), "Quite a bit" (3), and "Very much" (4). With 13 statements, the total score has a range of 0 to 52. The higher score corresponded to a higher quality of life. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 26
scores on a scalePegcetacoplanStandard of Care
Change From Baseline in Functional Assessment of Chronic Illness Therapy- (FACIT-Fatigue) Scale Score at Week 267.78 ± 1.2103.26 ± 2.113
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = 0.061 (P-value for baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: 4.51 · 95% CI -0.21 to 9.24
SecondaryPercentage of Subjects With Hb Normalization Levels at Week 26

Normalization of Hb levels defined as \>= 1x LLN at Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects With Hb Normalization Levels at Week 26
percentage of subjectsPegcetacoplanStandard of Care
Percentage of Subjects With Hb Normalization Levels at Week 2645.70
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = 0.001 · Difference: 0.3645 · 95% CI 0.1648 to 0.5642
SecondaryPercentage of Subjects With LDH Normalization at Week 26

The LDH normalization was defined as LDH \<= 1xupper limit of normal (ULN) of normal range at week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPPRC, LPRC, LPB or whole blood.

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects With LDH Normalization at Week 26
percentage of subjectsPegcetacoplanStandard of Care
Percentage of Subjects With LDH Normalization at Week 2665.70
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = <0.0001 · Difference: 0.5592 · 95% CI 0.3682 to 0.7502
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 26

The EORTC QLQ-C30 questionnaire (version 3.0) consisted of 30 questions comprised of both multi-item scales and single-item measures to assess overall quality of life in subjects. Questions were designated by functional scales, symptom scales, and global subject QOL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). Each scale has a range of 0% - 100%. A high scale score represents a higher response level. Baseline is defined as average of measurements prior to first dose of pegcetacoplan or on or prior to randomization of SoC. Post baseline missing values are imputed using multiple imputation method with Markov Chain Mont Carlo method.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 26
scores on a scalePegcetacoplanStandard of Care
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) Scores at Week 2618.90 ± 2.909-2.85 ± 5.703
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = 0.0006 (P-value for baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: 21.75 · 95% CI 9.35 to 34.16
SecondaryChange From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 26

The LASA consisted of 3 items asking respondents to rate their perceived level of functioning. Specific domains include activity level, ability to carry out daily activities, and an item for overall QOL. Their level of functioning was reported on a 0-100 scale with 0 representing "As low as could be" and 100 representing "As high as could be".

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 26
scores on a scalePegcetacoplanStandard of Care
Change From Baseline in Linear Analog Assessment (LASA) Scales Score at Week 2650.39 ± 9.062-5.39 ± 17.689
Statistical analysis
  • Pegcetacoplan vs Standard of Care · ANCOVA · p = 0.005 (P-value for baseline, strata and treatment is from LS mean of proc mixed and proc mianalyze based on parameter estimates.) · Ls mean difference: 55.79 · 95% CI 16.83 to 94.74
SecondaryPercentage of Subjects With ARC Normalization

Absolute reticulocyte count normalization is defined as ARC \< 1x ULN of the gender-specific normal range at week 26 in the absence of transfusion. Subjects who received a transfusion or withdraw from study or escaped from SoC to pegcetacoplan treatment group or lost to follow up without providing efficacy data at Week 26 were classified as non-responders. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

Time frame:
At Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects With ARC Normalization
percentage of subjectsPegcetacoplanStandard of Care
Percentage of Subjects With ARC Normalization60.05.6
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Cochran-Mantel-Haenszel · p = 0.0002 (Cochran-Mantel-Haenszel test is stratified by number of PRBC within 12 months prior to screening (\<4, ≥ 4) reported in EDC data.) · Difference: 0.4639 · 95% CI 0.2529 to 0.675
SecondaryNumber of Subjects With Failure of Hb Stabilization

Hb stabilization is defined as avoidance of a \>1 g/dL decrease in Hb levels from baseline through Week 26 in the absence of transfusion. Transfusion refers to any transfusion of PRBC, LDPRC, LPRC, LPB or whole blood.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects With Failure of Hb Stabilization
ParticipantsPegcetacoplanStandard of Care
Number of Subjects With Failure of Hb Stabilization418
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Stratified Wilcoxon · p = <0.0001 (Hazard ratio is based on cox proportional hazards model.) · Stratified hazard ratio: 0.02 · 95% CI 0.004 to 0.091
SecondaryTime to First PRBC Transfusion

Time to first-on-study PRBC transfusions during RCP were reported. Here NA indicates not estimable.

Time frame:
Up to Week 26
Reported as:
Median · weeks
Time to First PRBC Transfusion
weeksPegcetacoplanStandard of Care
Time to First PRBC TransfusionNA (NA to NA)7.000 (4.143 to 10.286)
Statistical analysis
  • Pegcetacoplan vs Standard of Care · Stratified Wilcoxon · p = <0.0001 · Stratified hazard ratio: 0.025 · 95% CI 0.005 to 0.121

Adverse events

Collected over Treatment-emergent adverse events were reported from the first dose of study medication and for up to 8 weeks after the last dose of study medication, approximately 34 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Pegcetacoplan1/46 (2.2%)6/46 (13%)35/46 (76.1%)
Standard of Care1/18 (5.6%)3/18 (16.7%)12/18 (66.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventOverall PegcetacoplanStandard of Care
Febrile neutropeniaBlood and lymphatic system disorders1/461/18
Bone marrow failureBlood and lymphatic system disorders0/461/18
ThrombocytopeniaBlood and lymphatic system disorders0/461/18
Pneumocystis jirovecii pneumoniaInfections and infestations0/461/18
Metabolic acidosisMetabolism and nutrition disorders0/461/18
Septic shockInfections and infestations1/461/18
Herpes virus infectionInfections and infestations0/461/18
Pulmonary tuberculosisInfections and infestations0/461/18
Urinary tract infectionInfections and infestations0/461/18
Respiratory failureRespiratory, thoracic and mediastinal disorders0/461/18
Most frequent other events
Showing 10 of 34
Most frequent other events
EventOverall PegcetacoplanStandard of Care
HypokalaemiaMetabolism and nutrition disorders6/462/18
Pain in extremityMusculoskeletal and connective tissue disorders6/460/18
Upper respiratory tract infectionInfections and infestations1/462/18
ArthralgiaMusculoskeletal and connective tissue disorders5/460/18
DizzinessNervous system disorders5/460/18
PyrexiaGeneral disorders4/460/18
HeadacheNervous system disorders4/460/18
EcchymosisSkin and subcutaneous tissue disorders3/460/18
ErythemaSkin and subcutaneous tissue disorders3/460/18
Viral infectionInfections and infestations3/460/18

Baseline characteristics

The intent-to-treat (ITT) set included all subjects assigned to treatment.

Age, Continuous
Age, Continuous(years)PegcetacoplanStandard of CareTotal
Mean42.2 ± 12.7049.1 ± 15.6444.5 ± 14.00
Age, Customized
Age, Customized(Participants)PegcetacoplanStandard of CareTotal
<65 years331447
>=65 and <75 years246
Sex: Female, Male
Sex: Female, Male(Participants)PegcetacoplanStandard of CareTotal
Female16824
Male191029
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PegcetacoplanStandard of CareTotal
Hispanic or Latino12214
Not Hispanic or Latino231639
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PegcetacoplanStandard of CareTotal
Black or African American202
American Indian or Alaska Native9211
Asian231639
Other101
08

Study locations

30 sites
  • Julian Coronel Medical Center
    Cali, Colombia
  • Research Center of the Colombian Clinical Life Cancer Foundation
    Medellín, Colombia
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Princess Margaret Hospital
    Kwai Chung, Hong Kong
  • Prince and Wales Hospital
    Sha Tin, Hong Kong
  • Hospital Ampang
    Ampang, Selangor 68000, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Hospital Universitario Dr.Jose Eleuterio Gonzalez
    Monterrey, Mexico
  • Hospital Cayetano Heredia
    Jesús María, Lima 15072, Peru
  • Hospital Cayetano Heredia
    San Martin de Porres, Lima 15102, Peru
  • Hospital Nacional Dos de Mayo
    Lima, 15003, Peru
  • Baguio General Hospital
    Benguet, 2600, Philippines
  • Perpetual Succour Hospital
    Cebu City, 6000, Philippines
  • Mary Mediatrix Medical Center
    Lipa City, 4217, Philippines
  • Makati Medical Centre
    Makati City, 1229, Philippines
  • The Medical City
    Pasig City, 1604, Philippines
  • St. Lukes Medical Centre
    Quezon City, 1112, Philippines
  • Independent Public Clinical Hospital
    Lubin, 20-081, Poland
  • Institute of Hematology and Transfusiology
    Warsaw, 02-776, Poland
  • EMC Medical Institute
    Wrocław, 50-220, Poland
  • Clinical Centre of Serbia
    Belgrade, Serbia
  • Singapore General Hospital (SGH)
    Singapore, 169608, Singapore
  • Ramathibodi Hospital
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Hospital for Tropical disease
    Bangkok, Thailand
  • Phramongkutklao Hospital
    Bangkok, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
  • Srinagaring Hospital
    Khon Kaen, 40002, Thailand
  • Thammasat University Hospital
    Pathum Thani, 12120, Thailand
  • Songklanagaring Hospital
    Songkhla, 90110, Thailand
09

References and documents

Publications

  • Del Pozo Martin Y. 2021 ASH annual meeting. Lancet Haematol. 2022 Feb;9(2):e92-e93. doi: 10.1016/S2352-3026(21)00384-7. Epub 2021 Dec 16. No abstract available. PubMed 34922648 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jun 2021, 21 months.

Results were first posted in Oct 2022, 1 year 3 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 21 months is close to that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2019
First posted
Sep 11, 2019
StartActual
Aug 27, 2019
Primary completionActual
Jun 23, 2021
CompletionActual
Jun 23, 2021
Results first posted
Oct 21, 2022
Last update
Oct 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04085601
Responsible party
Sponsor
First posted
Sep 11, 2019
Start date
Aug 27, 2019
Primary completion
Jun 23, 2021
Completion
Jun 23, 2021
Results posted
Oct 21, 2022
Last update
Oct 21, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion